Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Status:
Completed
Trial end date:
2020-06-11
Target enrollment:
Participant gender:
Summary
The hypothesis for this study is that the regimen consisting of fludarabine, melphalan and
bortezomib improves the progression free survival and the response rate compared to
historical controls of fludarabine and melphalan alone.
Phase:
Phase 2
Details
Lead Sponsor:
Hackensack Meridian Health Hackensack University Medical Center